Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Change in Account Payables (2017 - 2024)

Solid Biosciences' Change in Account Payables history spans 8 years, with the latest figure at $815000.0 for Q4 2024.

  • For Q4 2024, Change in Account Payables rose 508.21% year-over-year to $815000.0; the TTM value through Dec 2024 reached $2.2 million, up 388.61%, while the annual FY2024 figure was $2.2 million, 388.61% up from the prior year.
  • Change in Account Payables for Q4 2024 was $815000.0 at Solid Biosciences, down from $918000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $2.7 million in Q1 2023 and bottomed at -$5.9 million in Q4 2022.
  • The 5-year median for Change in Account Payables is $210500.0 (2022), against an average of -$301350.0.
  • The largest annual shift saw Change in Account Payables plummeted 1136.14% in 2022 before it skyrocketed 3766.2% in 2023.
  • A 5-year view of Change in Account Payables shows it stood at -$829000.0 in 2020, then surged by 168.76% to $570000.0 in 2021, then tumbled by 1136.14% to -$5.9 million in 2022, then soared by 102.27% to $134000.0 in 2023, then surged by 508.21% to $815000.0 in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Change in Account Payables are $815000.0 (Q4 2024), $918000.0 (Q3 2024), and $1.1 million (Q2 2024).